DOI 10.1021/acs.nanolett.6c02855
Nanotechnology-Driven Precision Diagnostics and Therapeutics for Preeclampsia.
Аннотация
Preeclampsia originates in placental dysfunction yet it is detected only after maternal hypertension and proteinuria or other organ damage emerge, by which point disease-modifying interventions are not available, and delivery of the baby and placenta remains the only cure. Nanotechnology offers a route to reduce this diagnostic-therapeutic latency. Nanostructured biosensors and liquid biopsy platforms detect placental proteins, cell-free RNA/DNA, and extracellular vesicles at femtomolar concentrations and in a multiplex manner, enabling earlier risk stratification when integrated with machine-learning models. In parallel, placenta-targeted lipid-, peptide-, polymeric-, dendrimeric-, and small extracellular vesicle-based nanocarriers deliver angiogenic mRNA, antiangiogenic siRNA, antioxidants, and immunomodulators selectively to the trophoblast cells while limiting fetal exposure. Placenta-on-a-chip platforms and ex vivo placental perfusion models provide human-relevant test beds for these systems. We critically appraise these advances, examine the safety-by-design, manufacturing bottlenecks, and regulatory constraints unique to obstetric nanomedicine, and outline the convergence of theranostics and digital health that could move preeclampsia care from reactive symptom management toward proactive, placenta-targeted monitoring and therapy.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.